) vaccines division, Sanofi Pasteur, recently announced the launch
of Sklice (ivermectin) Lotion, 0.5% in the US.
The Food and Drug Administration (FDA) had approved the product
for the topical treatment of head lice in patients aged 6 months
and above in February 2012. Sklice was added to Sanofi's portfolio
after the acquisition of Topaz Pharmaceuticals in October 2011.
Approval was granted on the basis of data from two identical
multi-center, double-blind and placebo-controlled phase III trials
evaluating the efficacy and safety of Sklice. The two phase III
studies enrolled 781 patients in total.
Sklice demonstrated an impressive efficacy profile with a
significantly higher number of patients in the Sklice arm being
louse-free as compared to the placebo arm. Sklice was also found to
be well tolerated and less than 1% of patients experienced side
effects like conjunctivitis, ocular hyperemia, eye irritation,
dandruff, dry skin and skin-burning sensation.
As per Centers for Disease Control and Prevention (CDC) data,
head lice infests approximately 6 to 12 million children between 3
to 11 years annually. The total cost of the disease (both direct
and indirect) is anticipated to be around $1 billion. Currently
available head lice topical treatments include
) Ovide (malathion) and
We expect Sanofi to contain operating costs in order to increase
earnings in the face of weakening sales of some key drugs. We also
expect the company to pursue bolt on acquisitions. We are pleased
with the company's efforts to develop its pipeline.
We currently have a Neutral recommendation on Sanofi. The stock
carries a Zacks #3 Rank (Hold rating) in the short run.
PERNIX THERAPTC (PTX): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
TARO PHARMA IND (TARO): Free Stock Analysis
To read this article on Zacks.com click here.